| Literature DB >> 29379433 |
Krysti L Todd1, Tessa Brighton1, Emily S Norton1, Samuel Schick1, Wendy Elkins2, Olga Pletnikova3, Richard H Fortinsky4, Juan C Troncoso3, Peter J Molfese5, Susan M Resnick2, Joanne C Conover1.
Abstract
Ventriculomegaly (expansion of the brain's fluid-filled ventricles), a condition commonly found in the aging brain, results in areas of gliosis where the ependymal cells are replaced with dense astrocytic patches. Loss of ependymal cells would compromise trans-ependymal bulk flow mechanisms required for clearance of proteins and metabolites from the brain parenchyma. However, little is known about the interplay between age-related ventricle expansion, the decline in ependymal integrity, altered periventricular fluid homeostasis, abnormal protein accumulation and cognitive impairment. In collaboration with the Baltimore Longitudinal Study of Aging (BLSA) and Alzheimer's Disease Neuroimaging Initiative (ADNI), we analyzed longitudinal structural magnetic resonance imaging (MRI) and subject-matched fluid-attenuated inversion recovery (FLAIR) MRI and periventricular biospecimens to map spatiotemporally the progression of ventricle expansion and associated periventricular edema and loss of transependymal exchange functions in healthy aging individuals and those with varying degrees of cognitive impairment. We found that the trajectory of ventricle expansion and periventricular edema progression correlated with degree of cognitive impairment in both speed and severity, and confirmed that areas of expansion showed ventricle surface gliosis accompanied by edema and periventricular accumulation of protein aggregates, suggesting impaired clearance mechanisms in these regions. These findings reveal pathophysiological outcomes associated with normal brain aging and cognitive impairment, and indicate that a multifactorial analysis is best suited to predict and monitor cognitive decline.Entities:
Keywords: aging; cognitive impairment; ependymal cells; gliosis; periventricular edema; ventriculomegaly
Year: 2018 PMID: 29379433 PMCID: PMC5771258 DOI: 10.3389/fnagi.2017.00445
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
Demographic and summary cognitive test scores for Alzheimer’s Disease Neuroimaging Initiative (ADNI) subjects.
| Mean | SD | Normal | Mild | Moderate | Severe | ||
|---|---|---|---|---|---|---|---|
| 185 | |||||||
| Male | 96 | ||||||
| Female | 89 | ||||||
| First | 74.47 | 7.08 | |||||
| Second | 76.51 | 7.11 | |||||
| First | 19.40 | 8.99 | 79 | 97 | 9 | 0 | |
| Second | 24.71 | 13.59 | 56 | 94 | 29 | 6 | |
| First | 26.52 | 2.67 | 103 | 78 | 4 | 0 | |
| Second | 24.04 | 4.47 | 55 | 93 | 36 | 1 | |
| First | 0.48 | 0.29 | 30 | 154 | 1 | 0 | |
| Second | 0.66 | 0.51 | 28 | 105 | 5 | 2 |
For cognitive tests, scale is shown under test name and the range is represented as normal → highest level of cognitive impairment.
Demographic information, summary cognitive test scores and biospecimen data for Baltimore Longitudinal Study of Aging (BLSA) subjects.
| Subject ID | CN1 | CN2 | CI1 | CI2 |
|---|---|---|---|---|
| Gender | M | F | F | M |
| Ages analyzed (Years) | 65–69 | 83–99 | 63–82 | 83–85 |
| MMSE score (30→0) | 28 (65), 29 (69) | 30 (83), 28 (99) | 30 (63) | 26 (83), 26 (85) |
| CDR score (0→3) | 0 (69) | 0 (83), 0.5 (99) | 3 (82) | 0.5 (83), 1 (85) |
| Trail making test A (s) | 16 (65), 16 (69) | 40 (83) | 35 (63) | 44 (83), 142 (85) |
| Trail making test B (s) | 32 (65), 36 (69) | 95 (83) | 98 (63) | 141 (83), 996 (85) |
| Blessed information memory concentration | 0 (65), 0 (69) | 0 (83), 5 (99) | 2 (63) | 3 (83), 7 (85) |
| Boston naming test (out of 60) | 58 (65), 59 (69) | 57 (83), 43 (99) | 60 (63) | 60 (83), 54 (85) |
| Category fluency (out of 60) | 52 (65), 55 (69) | 57 (83), 35 (99) | 52 (63) | 34 (83), 21 (85) |
| Letter fluency (out of 60) | 42 (65), 55 (69) | 53 (83), 37 (99) | 33 (63) | 27 (83), 25 (85) |
| Age at death | 70 | 99 | 82 | 86 |
| PMD (h) | 33.5 | 16 | 21 | 19 |
| Time between last scan and autopsy | 15 Months, 16 Days | Postmortem | Postmortem | 5 months, 11 Days |
Data shown for two cognitively normal (CN) and two cognitively impaired (CI) case studies. For cognitive tests, scale is shown under test name and the range is represented as normal → highest level of cognitive impairment. Age at time of scoring is indicated in parentheses. PMD, postmortem delay; s, seconds; h, hours.
Figure 1Cognitive scores worsen with increasing lateral ventricle (LV) volume and fluid-attenuated inversion recovery (FLAIR) periventricular hyperintensities (PVH) volume (Alzheimer’s Disease Neuroimaging Initiative, ADNI). (A) Scatter plot of 2-year difference in Alzheimer’s disease assessment scale (ADAS) score vs. 2-year difference in LV volume (top left panel) and 2-year difference in PVH volume (top right panel). Bar graphs in bottom panel show 2-year difference in LV volume (right) and PVH volume (left) in normal and cognitively impaired (CI) subjects as determined by ADAS score at the second time point. (B) Scatter plot of 2-year difference in Mini Mental State Exam (MMSE) score vs. 2-year difference in LV volume (top left panel) and 2-year difference in PVH volume (top right panel). Bar graphs in bottom panel show 2-year difference in LV volume (right) and PVH volume (left) in normal and CI subjects as determined by MMSE score at the second time point. (C) Column scatter plot of 2-year difference in LV volume (top left panel) or PVH volume (top right panel) for subjects with a stable Clinical Dementia Rating (CDR) score or increase in CDR score. Bar graphs in bottom panel show 2-year difference in LV volume (right) and PVH volume (left) in normal and CI subjects as determined by CDR score at the second time point. (D) Scatter plot of 2-year difference in PVH volume vs. 2-year difference in LV volume (left panel) and 2-year difference in LV volume vs. 2-year difference in PVH volume (right panel). For all bar and column scatter graphs statistical significance was determined using an unpaired t-test with Welch’s correction. All LV volumes are depicted as filled-in circles (scatter plots) and filled in bars (bar graphs), and PVH volumes are shown as open squares (scatter plots) and open bars (bar graphs).
Figure 2Ventricle expansion is minimal and ependymal cell coverage maintained in cognitively normal (CN) individuals (Baltimore Longitudinal Study of Aging, BLSA). Superior and inferior views of 3D volumetric representations of the LVs for CN1 (A) and CN2 (B). LV volumes at the indicated ages are overlaid (top panels) with base volumes shown in blue, expansion in red and stenosis in green. Corresponding immunolabeling of subject-matched biospecimens is shown below 3D representations, with lowercase (a–d) representing areas of the frontal and occipital horn locations from which tissue was dissected. GFAP highlights regional gliosis in red, AQP4 outlines ependymal cells in blue. Areas of intact ependymal cell coverage are outlined by a white dotted line. Scale bar 50 μm.
Figure 3Ventricle expansion and associated glial scar formation are more rapid and extensive with cognitive impairment. Superior and inferior views of 3D volumetric representations of the LVs for CI1 (A) and CI2 (B). LV volumes at the indicated ages are overlaid (top panels) with base volumes shown in blue, expansion in red, and stenosis in green. Corresponding immunolabeling of subject-matched biospecimens is shown below 3D representations, with lowercase (a–d) representing areas of the frontal and occipital horn locations from which tissue was dissected. GFAP highlights regional gliosis in red, AQP4 outlines ependymal cells in blue. Areas of intact ependymal cell coverage are outlined by a white dotted line. Scale bar 50 μm.
Figure 4Increased PVH volume correlates with vascular compromise, abnormal protein deposition, and decreased white matter integrity. (A) Superior and inferior views of 3D volumetric representation of the LVs (CN1 and CI2) at time point 1 (indicated first age; gray) overlaid with FLAIR PVH volume at time point 1 (indicated first age; blue) and time point 2 (indicated second age; red). A white box indicates area from which periventricular tissue for immunolabeling was dissected. (B) Immunolabeling of periventricular blood vessels using albumin (green). Intact blood vessels are indicated with a white arrowhead. Scale bar 25 μm. (C) Immunolabeling of periventricular astrocytes (GFAP; red) and hyperphosphorylated tau (PHF-1; green). Scale bar 25 μm. (D) Immunohistochemical labeling of periventricular Aβ42 accumulation (anti-Aβ42). Dense deposits are indicated with a white arrowhead while diffuse deposits are indicated with a black arrowhead. Scale bar 25 μm. (E) FA difference maps (between first and second time points) over first time point T1 structural images for both CN1 and CI2. A key showing colors denoting FA value differences is shown.
Figure 5Decreased white matter integrity with cognitive impairment in specific ROIs. (A) Top panels depict frontal ROI analyzed in CN1 and CI2. Bottom panel graphs show fractional anisotropy (FA) and mean diffusivity for CN1 and CI1 at time points 1 and 2 (CN1: 65 and 69, CI2: 83 and 85). (B) Top panels depict cingulum ROI analyzed in CN1 and CI2. Bottom panel graphs show FA and MD for CN1 and CI1 at time points 1 and 2. (C) Top panels depict occipital ROI analyzed in CN1 and CI2. Bottom panel graphs show FA and MD for CN1 and CI1 at time points 1 and 2. (D) Top panels depict inferior ROI analyzed in CN1 and CI2. Bottom panel graphs show FA and MD for CN1 and CI1 at time points 1 and 2. For all ROI graphs, the average FA values from each hemisphere are depicted.